Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Decrease in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a large decline in short interest in February. As of February 28th, there was short interest totalling 42,300 shares, a decline of 23.8% from the February 13th total of 55,500 shares. Approximately 2.3% of the company’s shares are sold short. Based on an average daily volume of 63,400 shares, the short-interest ratio is presently 0.7 days.

Lixte Biotechnology Price Performance

NASDAQ LIXT traded up $0.02 on Monday, hitting $1.23. 7,139 shares of the stock were exchanged, compared to its average volume of 317,640. Lixte Biotechnology has a 52-week low of $1.02 and a 52-week high of $4.40. The company has a market capitalization of $2.77 million, a price-to-earnings ratio of -0.71 and a beta of 0.19. The company’s 50-day moving average price is $1.92 and its two-hundred day moving average price is $1.91.

Hedge Funds Weigh In On Lixte Biotechnology

A hedge fund recently bought a new stake in Lixte Biotechnology stock. Atlas Legacy Advisors LLC purchased a new stake in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned approximately 0.56% of Lixte Biotechnology as of its most recent SEC filing. Institutional investors and hedge funds own 5.10% of the company’s stock.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.